Evidence map›Paper›PMID 41290258›Full record

ArticleJournal for immunotherapy of cancer2025

Development of a novel

Hongchuang Xu, Jingming Zhang, Zhuxin Wei, Xiao Wang, Min-Fu Yang, Xing Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongchuang XuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.ORCID http://orcid.org/0009-0004-2400-9621
Jingming ZhangDepartment of Nuclear Medicine, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-6132-9331
Zhuxin WeiDepartment of MRI, Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, China.ORCID http://orcid.org/0000-0001-8053-7120
Xiao WangDepartment of Nuclear Medicine, Peking University People's Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-3189-5666
Min-Fu YangDepartment of Nuclear Medicine, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China yangxing2017@bjmu.edu.cn minfuyang@126.com.
Xing YangDepartment of Nuclear Medicine, Peking University People's Hospital, Beijing, China yangxing2017@bjmu.edu.cn minfuyang@126.com.ORCID http://orcid.org/0000-0001-5186-4990

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy has emerged as a promising avenue for malignant tumors treatment, but methods to validate its in vivo antitumor activity remain limited. Granzyme B, a key mediator of immune-mediated cell death, is a potential biomarker for assessing immunotherapy efficacy. This study aimed to develop a radiotracer with high sensitivity and specificity for in vivo imaging of granzyme B.

methods10 granzyme B targeting inhibitors were synthesized and evaluated to improve binding affinity. The most promising compound was conjugated with 1,4,7-triazacyclononane-N,N',N"-triacetic acid chelator and radiolabeled with Al

results

conclusions

Indexed as

Fluorine RadioisotopesGranzymesImmunotherapyNeoplasmsRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansMiceFluorine-18Fluorine RadioisotopesGranzymesRadiopharmaceuticalsfMRI / PETImmune Checkpoint InhibitorImmunotherapyNatural killer - NK

Identifiers

PMID41290258
PMCPMC12645622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.